v3.26.3
Statement of Changes in Stockholders' Equity - USD ($)
Series A Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Beginning Balance at Jun. 30, 2024 $ 9 $ 131 $ 150,838,832 $ (139,374,895) $ 11,464,077
Beginning Balance (in shares) at Jun. 30, 2024 892,625 13,144,055      
Proceeds from sale of common stock in connection with equity financings net of issuance costs   $ 34 5,296,395   5,296,429
Proceeds from sale of common stock in connection with equity financings net of issuance costs (in shares)   3,351,096      
Series A preferred stock issued for employee stock compensation     60,722   60,722
Series A preferred stock issued for employee stock compensation (in shares) 13,092        
Common stock issued for consulting and legal services rendered   $ 1 115,499   115,500
Common stock issued for consulting and legal services rendered (in shares)   79,149      
Warrants issued to Scientific Advisory Board     679   679
Common stock issued for employee compensation     2,125   2,125
Common stock issued for employee compensation (in shares)   1,786      
Common stock issued for Directors fees     45,000   45,000
Common stock issued for Directors fees (in shares)   30,746      
Net loss       (9,466,966) (9,466,966)
Ending Balance at Jun. 30, 2025 $ 9 $ 166 156,359,252 (148,841,861) 7,517,566
Ending Balance (in shares) at Jun. 30, 2025 905,717 16,606,832      
Proceeds from sale of common stock in connection with equity financings net of issuance costs   $ 13 1,909,108   1,909,121
Proceeds from sale of common stock in connection with equity financings net of issuance costs (in shares)   1,264,988      
Series A preferred stock issued for employee stock compensation     49,619   49,619
Series A preferred stock issued for employee stock compensation (in shares) 13,092        
Proceeds from Registered Direct Offering of common stock and warrants net of financing cost of $893,243 (See Note 8)   $ 49 7,106,708   7,106,757
Proceeds from Registered Direct Offering of common stock and warrants net of financing cost of $893,243 (See Note 8) (in shares)   4,904,763      
Common stock issued for consulting and legal services rendered   $ 2 271,099   271,101
Common stock issued for consulting and legal services rendered (in shares)   195,558      
Warrants issued to Scientific Advisory Board     503   503
Common stock issued for employee compensation     1,731   1,731
Common stock issued for employee compensation (in shares)   1,786      
Common stock issued for Directors fees     45,001   45,001
Common stock issued for Directors fees (in shares)   34,381      
Net loss       (8,218,509) (8,218,509)
Ending Balance at Jun. 30, 2026 $ 9 $ 230 $ 165,743,021 $ (157,060,370) $ 8,682,890
Ending Balance (in shares) at Jun. 30, 2026 918,809 23,008,308